One of the first to treat patients with the recently FDA-approved Edwards SAPIEN Transcatheter Heart Valve. This therapy provides an important new treatment option for certain inoperable patients with severe, symptomatic native aortic valve stenosis who were studied in The PARTNER Trial, which determined transcatheter valve replacement was superior to standard therapeutic options such as medication or balloon aortic valvuloplasty.
